RomiDEPsin

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 803 publications

Integrated Patient-Derived Xenograft and Patient-Derived Cell Models Reveal Therapeutic Vulnerabilities Beyond Standard-of-Care Therapy in Endometrial Cancer.

Integrated Patient-Derived Xenograft and Patient-Derived Cell Models Reveal Therapeutic Vulnerabilities Beyond Standard-of-Care Therapy in Endometrial Cancer.

Journal: bioRxiv : the preprint server for biology
Published: August 20, 2026

Histone and non-histone protein acetylation in a tail regeneration model (Ambystoma mexicanum).

Histone and non-histone protein acetylation in a tail regeneration model (Ambystoma mexicanum).

Journal: Biology open
Published: June 01, 2026

From design to clinic: Medicinal chemistry and pharmacology of approved epigenetic drugs.

From design to clinic: Medicinal chemistry and pharmacology of approved epigenetic drugs.

Journal: European journal of medicinal chemistry
Published: May 19, 2026

Consensus transcriptional signature of dengue virus infection reveals coordinated interferon suppression and stress-response activation.

Consensus transcriptional signature of dengue virus infection reveals coordinated interferon suppression and stress-response activation.

Journal: Cell biochemistry and biophysics
Published: May 07, 2026

Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma.

Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma.

Journal: Clinical lymphoma, myeloma & leukemia
Published: April 21, 2026

Hypophosphatemia as a Potential Class Effect of Histone Deacetylase Inhibitors: Evidence from Disproportionality Analysis and Mendelian Randomization Analysis of Drug Targets.

Hypophosphatemia as a Potential Class Effect of Histone Deacetylase Inhibitors: Evidence from Disproportionality Analysis and Mendelian Randomization Analysis of Drug Targets.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: March 31, 2026

Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas. Blood Adv. 2025;9(16):4286-4305.

Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas. Blood Adv. 2025;9(16):4286-4305.

Journal: Blood advances
Published: January 29, 2026

Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database.

Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database.

Journal: Journal of pharmaceutical health care and sciences
Published: January 27, 2026

Cognitive and synaptic impairment induced by deficiency of autism risk gene Smarcc2 and its rescue by histone deacetylase inhibition.

Cognitive and synaptic impairment induced by deficiency of autism risk gene Smarcc2 and its rescue by histone deacetylase inhibition.

Journal: Molecular psychiatry
Published: January 09, 2026

Cardiac HDAC3 Disruption Contributes to HDAC Inhibitor-Induced QT Prolongation.

Cardiac HDAC3 Disruption Contributes to HDAC Inhibitor-Induced QT Prolongation.

Journal: Cells
Published: January 01, 2026

Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells.

Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells.

Journal: Bioorganic chemistry
Published: December 27, 2025

Clinical revival of romidepsin with nanoparticles.

Clinical revival of romidepsin with nanoparticles.

Journal: Blood
Published: December 04, 2025
Showing 1-12 of 803

Last Updated: 09/26/2026